L'effet amélioratif des cellules endothéliales hépatiques C-kit (+) avec une carence en Mertk sur une stéatohépatite non alcoolique
The prevalence of non-alcoholic fatty liver disease (NAFLD) has been steadily increasing, with 10-20% of affected individuals progressing to non-alcoholic steatohepatitis (NASH). NASH is pathologically characterized by hepatic inflammation, steatosis, and hepatocyte injury. Furthermore, this condition carries a significant risk of progression to advanced hepatic fibrosis (pathological Scheuer fibrosis stage F≥3), cirrhosis, and even hepatocellular carcinoma (HCC). In recent years, NASH has emerged as the leading contributor to the growing burden of cirrhosis worldwide, representing a major public health challenge. Despite the high incidence and clinical severity of NAFLD, there are currently no FDA-approved therapeutic agents for its management. Therefore, elucidating the molecular mechanisms underlying NAFLD-associated NASH progression is critical for developing targeted pharmacological interventions capable of preventing, ameliorating, or potentially reversing disease progression.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
I. Study Background Non-alcoholic fatty liver disease (NAFLD) has become one of the most prevalent liver disorders globally. Despite its high incidence and severity, no effective therapeutic agents currently exist. Existing treatments focus on symptomatic relief, such as hepatoprotection and enzyme reduction, rather than addressing the underlying pathogenesis. Therefore, elucidating the mechanisms driving the progression of NAFLD-related non-alcoholic steatohepatitis (NASH) and hepatic fibrosis is critical for developing preventive, ameliorative, or even curative strategies, holding significant strategic importance.
-
Role of LSECs in NAFLD Pathogenesis:
Liver sinusoidal endothelial cells (LSECs), the primary components of the hepatic sinusoidal endothelium, form a physical barrier regulating substance exchange between the hepatic parenchyma and circulation. As highly specialized endothelial cells (ECs) and the most abundant non-parenchymal cells (NPCs) in the liver, LSECs play pivotal roles in hepatic pathophysiology. Targeting LSEC function represents a promising approach to mitigate NAFLD progression and complications.
-
Heterogeneous Transcriptomic Features of LSEC Subpopulations in NAFLD:
Single-cell RNA sequencing (scRNA-seq) enables genome-wide amplification and sequencing at the single-cell level. In the liver, hepatocytes (HCs) and NPCs exhibit marked transcriptomic heterogeneity, underpinning metabolic and functional zonation. This highlights the potential of single-cell analysis in understanding liver diseases. However, scRNA-seq studies on LSECs in NAFLD remain unexplored.
-
Hypothesis: C-Kit(+)/Gas6(-)-LSEC Subpopulation Exacerbates NAFLD via Gas6/Mertk-Mediated Regulation of PINK1 Mitophagy:
Bone marrow-derived endothelial progenitor cells (EPCs), marked by C-Kit (CD117), may express C-Kit in ECs under pathological conditions. Gas6, a ligand for TAM receptors (Tyro3, Axl, Mertk), activates downstream signaling cascades regulating cell migration, inflammation, survival, and mitophagy. In NAFLD, Gas6/Mertk exhibits cell-specific roles : Anti-inflammatory in hepatic macrophages; Pro-fibrotic in hepatic stellate cells (HSCs); Protective in hepatocytes (HCs). However, the role of Gas6/Mertk in LSECs during NAFLD remains unknown. Mitochondrial dysfunction is a hallmark of NAFLD, and impaired mitophagy (e.g., PINK1 deficiency) exacerbates hepatic inflammation, steatosis, and fibrosis. Emerging evidence suggests Gas6/Mertk enhances mitophagy to preserve mitochondrial function. For instance, Mertk-/- mice exhibit cardiomyocyte mitochondrial dysfunction, and Gas6 promotes mitophagy.
Our preliminary scRNA-seq data from HFD/ND mice identified a unique C-Kit(+)/Gas6(-)-LSEC subpopulation. These LSECs induced mitophagy impairment in co-cultured HCs/HSCs, manifesting as mitochondrial senescence, oxidative stress, HSC activation, HC lipid deposition, and inflammation. Investigating how this subpopulation drives NAFLD progression will unveil novel pathophysiological mechanisms and therapeutic targets, forming the basis of this study.
II. Study Objectives To elucidate the expression levels of C-Kit and Gas6/Mertk ligand-receptor pairs in liver tissues of NAFLD patients.
III. Study Procedures
(1) Inclusion and Exclusion Criteria
- Inclusion Criteria: NAFLD diagnosis per Guidelines for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (2018 Edition). Age 18-65 years.
- Exclusion Criteria: Cirrhosis (compensated or decompensated), hepatocellular carcinoma, active viral hepatitis (HBV, HCV), primary biliary cholangitis, primary sclerosing cholangitis, recent history of illicit drug use, alcohol intake≥20 g/day for women and ≥30 g/day for men, current pregnancy or breastfeeding, severe comorbidities.
(2) Study Design
-
Liver Biopsy and Tissue Collection:
Ultrasound-guided liver biopsy in 6 NAFLD patients. Histopathological evaluation (HE, Masson staining) for NASH and fibrosis (NAS and Scheuer scoring). Clinical data collection and liver tissue storage (-80°C).
-
Expression Analysis of C-Kit and Mertk:
Immunofluorescence co-staining of liver tissues. 3. Statistical Analysis: Compare C-Kit and Mertk expression levels in mild and severe NAFLD patients.
(3) Enrollment and Workflow
-
Baseline Data Collection:
①Demographic and clinical parameters: name, sex, age, ethnicity, birthdate, height, weight, disease onset, contact information.
② Laboratory tests: CBC, ALT, AST, TBIL, TG, cholesterol, glucose, total protein, albumin.
③Clinical assessments: blood pressure, BMI, abdominal ultrasound, FibroScan.
-
Biopsy Protocol:
- Ultrasound-guided percutaneous liver biopsy within 1 month of enrollment. ②Tissue specimen requirements: ≥3 mm diameter, 5-8 mm length. ③Storage: -80°C for C-Kit and Mertk gene analysis.
IV. Expected Outcomes Clarify the regulatory relationship between C-Kit (+) LSECs and the Gas6-Mertk signaling pathway in NAFLD patient liver tissues.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Contacts et emplacements
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200120
- Shanghai East Hospital (East Hospital Affiliated To Tongji University)
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population comprised adults with NAFLD confirmed by imaging (ultrasound, CT, or MRI), excluding secondary causes (e.g., alcohol consumption >30/20 g/day for men/women, viral hepatitis, or steatogenic medications). . Exclusion criteria included Cirrhosis (compensated or decompensated), hepatocellular carcinoma, primary biliary cholangitis, primary sclerosing cholangitis, recent history of illicit drug use, current pregnancy or breastfeeding, severe comorbidities. NAFLD severity was categorized using non-invasive fibrosis scores (NFS) or liver biopsy (steatosis, inflammation, fibrosis staging).
La description
Inclusion Criteria:
- Clinical diagnosis of Non-Alcoholic Fatty Liver Disease
- Age 18-65 years
Exclusion Criteria:
- Cirrhosis (compensated or decompensated)
- Hepatocellular carcinoma
- Active viral hepatitis (HBV, HCV)
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Recent history of illicit drug use
- Alcohol intake≥20 g/day for women and ≥30 g/day for men
- Current pregnancy or breastfeeding
- Severe comorbidities.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: CROSS_SECTIONAL
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mertk expression levels of liver tissues
Délai: From enrollment to the end of treatment at 4 weeks
|
Compare Mertk expression levels between mild and severe NAFLD patients. |
From enrollment to the end of treatment at 4 weeks
|
|
C-Kit expression levels of liver tissues
Délai: From enrollment to the end of treatment at 4 weeks
|
Compare C-Kit expression levels between mild and severe NAFLD patients. |
From enrollment to the end of treatment at 4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- Approval No.2024YS-050
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .